Compare CCCC & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCCC | TCPC |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | 24900 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.7M | 346.5M |
| IPO Year | 2020 | 2006 |
| Metric | CCCC | TCPC |
|---|---|---|
| Price | $3.88 | $4.13 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 2 |
| Target Price | ★ $12.20 | $3.50 |
| AVG Volume (30 Days) | ★ 2.3M | 872.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 18.23% |
| EPS Growth | ★ 16.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,947,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $1.69 | $3.08 |
| 52 Week High | $5.17 | $7.28 |
| Indicator | CCCC | TCPC |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 64.06 |
| Support Level | $3.40 | $4.03 |
| Resistance Level | $4.49 | $4.25 |
| Average True Range (ATR) | 0.25 | 0.12 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 51.70 | 69.14 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.